Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Payment Roundup: Pass-Through Reforms, Packaging And More

This article was originally published in The Gray Sheet

Executive Summary

Key device updates in CMS's latest payment rules include reforms to the hospital outpatient pass-through payment process for new technology, the agency's continued march forward on "comprehensive" outpatient procedure payments, scaled-back physician cuts for radiation oncology and reimbursement for transoral GERD procedures.

You may also be interested in...



Policy Briefs: What's New From FDA And CMS

Updates include an FDA safety communication for the Lariat suture device addressing use for left atrial appendage closure, new FDA draft guidance documents, and CMS proposals to cut radiation therapy payments and launch new payment models for hip and knee replacements.

New EU Filings

Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma

Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel